Alcázar-Arroyo R, Portolés J, López-Sánchez P, et al. - Given that COVID-19 patients receiving hemodialysis (HD) carry a high mortality, therefore, by performing this prospective observational analysis of a large HD cohort, researchers sought to determine the value of RT-PCR as well as the dynamic alterations of antibodies (ELISA IgM+IgA and IgG). A diagnosis of symptomatic COVID-19 was received by 136 (16.8%) of 808 HD patients from March 1 to April 15, 2020, by using nasopharyngeal RT-PCR and 42/136 (31%) died during this time frame. In the second fortnight of April, 763 of the surviving patients were examined for RT-PCR and anti-SARS-CoV-2 antibodies. At this point, anti-SARS-CoV-2 antibodies were present in 69/91 (75,8%) symptomatic COVID-19 patients. Higher likelihood of an adequate serologic response (defined as the development of anti-SARS-CoV2 antibodies that persisted at 4 weeks) was observed in cases with symptomatic COVID-19 vs in asymptomatic SARS-CoV2 infection (OR 4.04 [2.04-7.99] corrected for age, Charlson score and time on HD. According to findings, clinical presentation was the factor on which depended the anti-SARS-CoV-2 antibody immune response in HD patients, and earlier antibody titers decay was evident in this patient population relative to previously noted for the general population. This inadequate immune response gives rise to questions regarding the efficacy of future vaccines.